2Lam AY, Elmer GW, Mohutsky MA. Ann Pharmacother,2001, 35: 1199-1201.
3Fugh Berman A. Lancet, 2000, 355(9198): 134-138.
4Howard PA. Guidelines for stroke prevention in patients with atrial fibrillation [J]. Drugs, 1999, 58: 997-1009.
5British committee for standards in haematology. Guidelines on oral anticoagulation: third edition [J]. Brit J Harm, 1998. 101: 373.
6Cannegieter S, Rosendaal F, Wintzen, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves[J]. New Engl J Med, 1995, 333: 11.
7郑兴,尉挺.现代内科治疗学[M].北京:人民军医出版社,1994.221.
8Holbrook A, Wells P, Crowther N. Pharmacokinetics and drug interactions with warfarin. In: Poller L, Hirsh J, ed. Oral anticoagalants [M]. London: Arnold, 1996.30.
9Gibbar-Clements T, Shirrell D, Dooley R, et al. The challenge of warfarin therapy [J]. Am J Nurs, 2000, 100 (3): 38-40.
10Robert GH,David GS,Easton JD,et al.Prevention of stroke in patients with nonvalvular atrial fibrillation[J].Neurology,1998, 51: 674
8Hurlen M, Abdelnoor M, smith P, et al. Warfa- rin, aspirin, or both after myocardial infarction [J]. N Engl J Med,2002,347(6) :969.
9Brodsky SV, Nadasdy T, Rovin BH, et al. War- farin- related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate [ J ]. Kidney Int,2011,80(2) :181 - 189.
10Abt AB, Carroll LE, Mohler JH. Thin basement membrane disease and acute renal failure sec- ondary to gross hematuria and tubular necrosis [J]. Am J Kidney Dis,2000,35 (3):533 - 536.
